Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
The BiCNU brand and generic market had U.S. sales of approximately US $ 19.4 million MAT for the most recent twelve months ending in August 2021, according to IQVIA Health
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The cloud-based platform enables long-term brain monitoring towards personalized treatment
Ryaltris is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
Subscribe To Our Newsletter & Stay Updated
